Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Capitalizing on small-cap market volatility and rate pressures to initiate new positions in asset-backed industrial and financial compounders, while harvesting gains from takeover targets.
Full Quick Take
Capitalizing on small-cap market volatility and rate pressures to initiate new positions in asset-backed industrial and financial compounders, while harvesting gains from takeover targets.
Baron Asset Fund outperformed by 443 basis points in Q2 2026 despite headwinds from narrow AI-driven market leadership, powered by SpaceX's historic IPO and 3,000%+ appreciation.
Full Quick Take
Baron Asset Fund outperformed by 443 basis points in Q2 2026 despite headwinds from narrow AI-driven market leadership, powered by SpaceX's historic IPO and 3,000%+ appreciation.
Aristotle Value underperformed in Q2 2026 due to deliberate underexposure to AI infrastructure semiconductors, which the manager views as transient scarcity earnings destined to normalize.
Full Quick Take
Aristotle Value underperformed in Q2 2026 due to deliberate underexposure to AI infrastructure semiconductors, which the manager views as transient scarcity earnings destined to normalize.
TCW's concentrated large cap growth fund underperformed in Q2 2026 despite strong absolute returns, as AI infrastructure spending accelerated toward $1 trillion annually.
Full Quick Take
TCW's concentrated large cap growth fund underperformed in Q2 2026 despite strong absolute returns, as AI infrastructure spending accelerated toward $1 trillion annually.
Trailing its benchmark's 24.02% as factor headwinds from the risk-on rally overwhelmed positive stock selection. The portfolio's quality orientation and lower-beta positioning lagged as the market rewarded speculative, high-momentum names following geopolitical de-escalation.
Full Quick Take
Trailing its benchmark's 24.02% as factor headwinds from the risk-on rally overwhelmed positive stock selection. The portfolio's quality orientation and lower-beta positioning lagged as the market rewarded speculative, high-momentum names following geopolitical de-escalation.
Underperforming on AI enthusiasm but maintaining long-term outperformance. Samsung rallied on AI-driven memory demand while BMW fell on China weakness.
Full Quick Take
Underperforming on AI enthusiasm but maintaining long-term outperformance. Samsung rallied on AI-driven memory demand while BMW fell on China weakness.
Oakmark International Small Cap underperformed in Q3 but used market volatility to add quality positions at attractive valuations. The fund added engineering services provider Alten and auto components spinoff Aumovio while increasing positions in cyclically depressed names.
Full Quick Take
Oakmark International Small Cap underperformed in Q3 but used market volatility to add quality positions at attractive valuations. The fund added engineering services provider Alten and auto components spinoff Aumovio while increasing positions in cyclically depressed names.
Edgewood's concentrated growth strategy underperformed in Q3 due to stock-specific issues, not fundamental deterioration. The firm maintains high conviction in AI infrastructure buildout (28% of portfolio) and quality growth companies.
Full Quick Take
Edgewood's concentrated growth strategy underperformed in Q3 due to stock-specific issues, not fundamental deterioration. The firm maintains high conviction in AI infrastructure buildout (28% of portfolio) and quality growth companies.
Small cap fund underperformed in volatile Q1 2025 as trade tensions and AI competition concerns pressured markets. Portfolio benefited from Inari Medical's $4.7B Stryker acquisition and strong results from GeneDx and Guidewire, while Agilysys, Xometry, and FTAI detracted.
Full Quick Take
Small cap fund underperformed in volatile Q1 2025 as trade tensions and AI competition concerns pressured markets. Portfolio benefited from Inari Medical's $4.7B Stryker acquisition and strong results from GeneDx and Guidewire, while Agilysys, Xometry, and FTAI detracted.
Underperforming its benchmark amid tariff uncertainty and small-cap underperformance. The strategy's defensive positioning and valuation discipline provided some downside protection while healthcare holdings faced mixed results.
Full Quick Take
Underperforming its benchmark amid tariff uncertainty and small-cap underperformance. The strategy's defensive positioning and valuation discipline provided some downside protection while healthcare holdings faced mixed results.
Brown Capital's International All Company Fund underperformed in Q1 2025 as growth stocks lagged value, but the manager remains confident in their Exceptional Growth Company strategy.
Full Quick Take
Brown Capital's International All Company Fund underperformed in Q1 2025 as growth stocks lagged value, but the manager remains confident in their Exceptional Growth Company strategy.
Parnassus Growth Equity outperformed in a volatile quarter driven by Consumer Discretionary positioning and defensive stock selection. While AI and semiconductor stocks faced pressure from policy uncertainty, the fund opportunistically added quality names like Synopsys and ASML.
Full Quick Take
Parnassus Growth Equity outperformed in a volatile quarter driven by Consumer Discretionary positioning and defensive stock selection. While AI and semiconductor stocks faced pressure from policy uncertainty, the fund opportunistically added quality names like Synopsys and ASML.
Small-cap growth fund outperformed in Q4 2024 with 3.90% return, driven by AI-powered lending platform Upstart, genetic testing leader Natera, and semiconductor company Semtech. Portfolio focused on secular themes including AI, cloud computing, and genomic innovations.
Full Quick Take
Small-cap growth fund outperformed in Q4 2024 with 3.90% return, driven by AI-powered lending platform Upstart, genetic testing leader Natera, and semiconductor company Semtech. Portfolio focused on secular themes including AI, cloud computing, and genomic innovations.
Roughly in line with its benchmark. Despite near-term policy uncertainty under the new administration, the manager remains bullish on long-term health care innovation, particularly in biotechnology, medical devices, and life sciences tools.
Full Quick Take
Roughly in line with its benchmark. Despite near-term policy uncertainty under the new administration, the manager remains bullish on long-term health care innovation, particularly in biotechnology, medical devices, and life sciences tools.
Biotech funding dried up, hurting Charles River Labs, while software names like Guidewire showed recovery. The manager added genomics play Natera and maintains long-term conviction despite macro headwinds affecting growth company fundamentals.
Full Quick Take
Biotech funding dried up, hurting Charles River Labs, while software names like Guidewire showed recovery. The manager added genomics play Natera and maintains long-term conviction despite macro headwinds affecting growth company fundamentals.
Outperforming value benchmarks through concentrated positions in quality businesses. Strong performance from medical device holdings including Spok and UFP Technologies.
Full Quick Take
Outperforming value benchmarks through concentrated positions in quality businesses. Strong performance from medical device holdings including Spok and UFP Technologies.
Meridian Small Cap Growth outperformed in Q4 2023 with a risk-first approach targeting high-quality companies with recurring revenue. Strong performance from Mirion Technologies and CarGurus offset weakness in medical technology holdings.
Full Quick Take
Meridian Small Cap Growth outperformed in Q4 2023 with a risk-first approach targeting high-quality companies with recurring revenue. Strong performance from Mirion Technologies and CarGurus offset weakness in medical technology holdings.
Focusing on small, customer-centric companies with smart management teams. The fund maintains a concentrated approach, recently harvesting losses and holding higher cash due to geopolitical tensions.
Full Quick Take
Focusing on small, customer-centric companies with smart management teams. The fund maintains a concentrated approach, recently harvesting losses and holding higher cash due to geopolitical tensions.
Healthcare drove positive security selection through biotech pipeline progress, while medical devices faced GLP-1 headwinds. Manager added industrial and software positions while harvesting select holdings.
Full Quick Take
Healthcare drove positive security selection through biotech pipeline progress, while medical devices faced GLP-1 headwinds. Manager added industrial and software positions while harvesting select holdings.
The fund added two small-cap positions crossing institutional size thresholds: UFP Technologies, a medical device manufacturer targeting 25% IRR potential, and MYR Group, an electrical contractor benefiting from infrastructure spending and energy transition.
Full Quick Take
The fund added two small-cap positions crossing institutional size thresholds: UFP Technologies, a medical device manufacturer targeting 25% IRR potential, and MYR Group, an electrical contractor benefiting from infrastructure spending and energy transition.
Healthcare, and technology. Key positions like Amazon and GE Healthcare show margin expansion potential while the team maintains defensive positioning against macro risks.
Full Quick Take
Healthcare, and technology. Key positions like Amazon and GE Healthcare show margin expansion potential while the team maintains defensive positioning against macro risks.
ClearBridge's Large Cap Growth Strategy delivered its third consecutive quarter of outperformance through improved stock selection, particularly in AI-beneficiary Nvidia and recovering names like Meta and Netflix.
Full Quick Take
ClearBridge's Large Cap Growth Strategy delivered its third consecutive quarter of outperformance through improved stock selection, particularly in AI-beneficiary Nvidia and recovering names like Meta and Netflix.
ClearBridge's value strategy navigated Q1 2023 banking turmoil by favoring large, diversified banks while opportunistically adding to healthcare positions including McKesson and Becton Dickinson.
Full Quick Take
ClearBridge's value strategy navigated Q1 2023 banking turmoil by favoring large, diversified banks while opportunistically adding to healthcare positions including McKesson and Becton Dickinson.
Outpacing the Russell 2000 Growth by 619 basis points through strong stock selection and favorable sector allocation. Top performers included AAON, Axon Enterprise, and Stevenato Group.
Full Quick Take
Outpacing the Russell 2000 Growth by 619 basis points through strong stock selection and favorable sector allocation. Top performers included AAON, Axon Enterprise, and Stevenato Group.
Alphyn matched the S&P 500 in Q1 despite WANdisco's accounting fraud requiring a 50% markdown. Burford's $1.9-3.3 billion Argentina victory and strong performance from Fairfax and Exor offset the damage.
Full Quick Take
Alphyn matched the S&P 500 in Q1 despite WANdisco's accounting fraud requiring a 50% markdown. Burford's $1.9-3.3 billion Argentina victory and strong performance from Fairfax and Exor offset the damage.
Strategic additions of Boston Scientific, Broadcom, and Fair Isaac capitalize on medical device innovation, AI semiconductor growth, and credit analytics dominance.
Full Quick Take
Strategic additions of Boston Scientific, Broadcom, and Fair Isaac capitalize on medical device innovation, AI semiconductor growth, and credit analytics dominance.
Conestoga SMid Cap outperformed in Q1 2023 with 10.01% returns, benefiting from rotation into quality growth stocks after 2022's underperformance. Strong stock selection in Healthcare and Industrials, plus underweights to troubled Energy and Financials sectors drove results.
Full Quick Take
Conestoga SMid Cap outperformed in Q1 2023 with 10.01% returns, benefiting from rotation into quality growth stocks after 2022's underperformance. Strong stock selection in Healthcare and Industrials, plus underweights to troubled Energy and Financials sectors drove results.